DNA files 8-K with Exhibit 99.1 for Q3 2025 results

Rhea-AI Filing Summary

Ginkgo Bioworks (DNA) furnished an 8-K announcing it issued a press release with its financial results for the third quarter ended September 30, 2025. The press release is provided as Exhibit 99.1.

The filing, dated November 6, 2025, is an administrative disclosure under Item 2.02 (Results of Operations and Financial Condition) and includes the Inline XBRL cover page file as Exhibit 104.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001830214FALSE00018302142025-11-062025-11-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

______________________________________________________________

FORM 8-K

______________________________________________________________

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 6, 2025

______________________________________________________________

GINKGO BIOWORKS HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

______________________________________________________________

Delaware

001-40097

87-2652913

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

27 Drydock Avenue

8th Floor

Boston, MA 02210

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: (877) 422-5362

(Former name or former address, if changed since last report)

______________________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Class A common stock, par value $0.0001 per share

DNA

NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02. Results of Operations and Financial Condition.

On November 6, 2025, Ginkgo Bioworks Holdings, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2025. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits.

Exhibit Number						Description
99.1						Press Release, issued by Ginkgo Bioworks Holdings, Inc. on November 6, 2025
104						Cover Page Interactive Data File (embedded within the Inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			GINKGO BIOWORKS HOLDINGS, INC.
Date: November 6, 2025			By:			/s/ Steven Coen
			Name:			Steven Coen
			Title:			Chief Financial Officer

FAQ

What did Ginkgo Bioworks (DNA) announce in this 8-K?

The company furnished a press release with financial results for the quarter ended September 30, 2025, included as Exhibit 99.1.

Which period does the press release cover for Ginkgo Bioworks (DNA)?

It covers the third quarter ended September 30, 2025.

When was the 8-K dated for Ginkgo Bioworks (DNA)?

The report is dated November 6, 2025.

What exhibits are included with the Ginkgo Bioworks (DNA) 8-K?

Exhibit 99.1 (press release) and Exhibit 104 (Inline XBRL cover page file).

Under which item did Ginkgo Bioworks (DNA) furnish its results?

The disclosure is under Item 2.02: Results of Operations and Financial Condition.

What is Ginkgo Bioworks (DNA)'s trading symbol and exchange?

The Class A common stock trades on the NYSE under the symbol DNA.